@GranulesIndia earnings call transcript Q2fy21
No longer a 5 product company
22 launched products
PAT growth up 80% H1fy21 compared to H1fy20,due to fast approval of filed ANDAs,rapid scale up production
Ebidta,PAT > Rev growth- better product mix,sales,op efficiency
#Stocks
No longer a 5 product company
22 launched products
PAT growth up 80% H1fy21 compared to H1fy20,due to fast approval of filed ANDAs,rapid scale up production
Ebidta,PAT > Rev growth- better product mix,sales,op efficiency
#Stocks
32 approved ANDAs(6 yet to launch),13 waiting for approval
Expect 1 MUPS tech based ANDA in Q3 or Q4
Construction MUPS block on track,commercialize Q3fy22
High vol MUPS products & APIs next major driver
Q1fy21 recall of $2 mn tabs Metformin 750mg,this Q 1mn reversed into books
Expect 1 MUPS tech based ANDA in Q3 or Q4
Construction MUPS block on track,commercialize Q3fy22
High vol MUPS products & APIs next major driver
Q1fy21 recall of $2 mn tabs Metformin 750mg,this Q 1mn reversed into books
Covid expense 19.3 crs in H1fy21
Rev Q1fy20/21 858/700 cr up23% yoy
Gross margin moved 48.6 to 57.9% YoY thru new launches,increased finished dosages,product rationalization in PFI & Finished dosages
PAT 164 vs 96 crs,up 71% yoy
#Stocks #pharma #Nifty #sensex
Rev Q1fy20/21 858/700 cr up23% yoy
Gross margin moved 48.6 to 57.9% YoY thru new launches,increased finished dosages,product rationalization in PFI & Finished dosages
PAT 164 vs 96 crs,up 71% yoy
#Stocks #pharma #Nifty #sensex
Reduced gross debt 870 cr in Q1 to 861 in Q2, term debt 480 & short term debt 381 crs
Spent 22 crs on R&D all of which is written off
Expect 1st EU approval in Q4
Filed 4 DMFs,received 4 approvals
Free cash at end Q2 52.2 crs
12 crs paid in dividends
Repaid long term debt 52 cr
Spent 22 crs on R&D all of which is written off
Expect 1st EU approval in Q4
Filed 4 DMFs,received 4 approvals
Free cash at end Q2 52.2 crs
12 crs paid in dividends
Repaid long term debt 52 cr
Key driver for @GranulesIndia
Launches,approvals in US mkt
EU approvals,possibly 1 in Q4
Acquisition of new ANDAs
Launch of MUPS tech based products
Shift from partner based US sales to thru own franchise resulting in increased inventory & receivable days
Launches,approvals in US mkt
EU approvals,possibly 1 in Q4
Acquisition of new ANDAs
Launch of MUPS tech based products
Shift from partner based US sales to thru own franchise resulting in increased inventory & receivable days
Receivable 158cr,blocked in inventory 184 crs due to stockpiling of 3-4 months before new launches
Dependent on Para-aminophenol key raw Material for Paracetamol on China
Contribution of 70% from core mols to revenue in Q2
Expect PAT growth 80% this year,CAGR of 30% next few yrs
Dependent on Para-aminophenol key raw Material for Paracetamol on China
Contribution of 70% from core mols to revenue in Q2
Expect PAT growth 80% this year,CAGR of 30% next few yrs
1 MUPS tech based product launch expected in Q3,Q4 ,addressable mkt size $ 205 mn generic value with 3 to 4 active players
CAPEX of 400 crs lined up next 2 yrs ,80 cr for #API & rest MUPS,capex thru internal accruals
No comments on takeover bids,focus value creation
#Stocks
CAPEX of 400 crs lined up next 2 yrs ,80 cr for #API & rest MUPS,capex thru internal accruals
No comments on takeover bids,focus value creation
#Stocks
Addressable mkt US size for MUPS $2.8 Bn
Integration betn unit 4,5 API & MUPS to support US generic & MUPS tech business
Majority API growth from US mkt
Diversify business into EU,LATAM to decrease US dependence by Fy23
APIs required for Formulations to be developed by #granules
Integration betn unit 4,5 API & MUPS to support US generic & MUPS tech business
Majority API growth from US mkt
Diversify business into EU,LATAM to decrease US dependence by Fy23
APIs required for Formulations to be developed by #granules
Revenue
Fy23 expected in %
EU 28
US 43
LATAM 12
ROW 17
Indian pharma getting more approvals from #usfda,less price erosion,shift to decrease of China dependence
@GranulesIndia
Unroll
@threadreaderapp
Compile
@threader_app
@thescorpionphil
@tycoonmindset05
@nid_rockz
Fy23 expected in %
EU 28
US 43
LATAM 12
ROW 17
Indian pharma getting more approvals from #usfda,less price erosion,shift to decrease of China dependence
@GranulesIndia
Unroll
@threadreaderapp
Compile
@threader_app
@thescorpionphil
@tycoonmindset05
@nid_rockz
• • •
Missing some Tweet in this thread? You can try to
force a refresh
